PALO ALTO, Calif.--(BUSINESS WIRE)--Science Exchange, the leading marketplace for outsourced R&D™, announces a collaboration with AUM BioTech, an emerging Philadelphia-based startup, to advance genetic research and significantly cut short drug discovery and development time. Science Exchange will now offer AUM BioTech’s self-delivering, next-generation RNA silencing products and alternatives to conventional CRISPR, siRNA and shRNA approaches.
As a part of this alliance, Science Exchange users will get instant access to AUM BioTech’s 300,000-plus customized and cutting-edge RNA silencing products targeting thousands of genetic targets powered by proprietary FANA technology, a technology platform composed of antisense oligonucleotide (AON) chemistries. These products can be used to target messenger RNA (mRNA), microRNA (miRNA) and long non-coding (lncRNA) for a broad spectrum of genetic studies. They can also be used to target viral, fungal and bacterial RNA. AUM BioTech’s FANA antisense oligonucleotides (FANA ASOs) can be self-delivered both in in vitro and in vivo models without the use of any conjugates, carriers or formulations and can be used for basic and translational research. Such products will significantly benefit the biomedical scientific community working on difficult-to-transfect primary cells, including, but not limited to B-Cells, T-cells, macrophages, neuronal cells and primary cells from diseased donors. It is also important to mention that researchers working with animal models can use FANAs for their preclinical studies via multiple routes of administration.
“With FANA, our goal is to shorten the drug discovery and development time and help bring clinical compounds to market much faster,” said Veenu Aishwarya, founder and CEO of AUM BioTech. “This strategic alliance with Science Exchange will grant its users on-demand access to our FANA technology and help them reduce the time and effort needed to understand the function of genes and their link to diseases.”
“AUM BioTech is an innovative company that has developed revolutionary genetic research products to significantly advance biomedical R&D and fast-track drug discovery, leading to more effective therapeutic development,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. "We are thrilled to collaborate with AUM BioTech and further advance our shared goal to help the global scientific community find cures for diseases.”
About Science Exchange
Science Exchange is the world's leading marketplace for outsourced R&D™, providing large R&D organizations with the fastest path from discovery through development and commercialization. Science Exchange includes an efficient source-to-secure platform for ordering 6,000+ services from a network of more than 2,500 qualified outsourced research providers, all with pre-established contracts in place that protect client intellectual property and confidentiality. The platform increases access to innovation and improves productivity, freeing scientists from administrative tasks and delays associated with sourcing, establishing and managing service provider contracts. Additionally, the Science Exchange enterprise program enables large R&D organizations to consolidate research outsourcing spend into a single strategic relationship, driving efficiency, improving transparency and oversight, and delivering cost savings. Since being founded in 2011, Science Exchange has raised more than $58 million from Norwest Venture Partners, Maverick Capital Ventures, Union Square Ventures, Collaborative Fund, Index Ventures, OATV, the YC Continuity Fund, and others. For more information, visit www.ScienceExchange.com. Follow the company on Twitter @ScienceExchange, Facebook and LinkedIn.
About AUM BioTech
AUM BioTech is a biotechnology company that offers solutions and products for genetic research using next-generation RNA silencing technology in diverse life science verticals including biomedical research, medicine, and agriculture. AUM's next generation FANA Antisense Oligonucleotide (FANA ASO) technology is globally being used by biomedical scientists and researchers working on basic, transitional and preclinical research. FANA ASO technology can be used to silence or regulate RNA modalities such as – mRNA, microRNA and long non-coding RNA. AUM's next generation FANA technology provides alternatives to CRISPR, siRNA and shRNA approaches. FANA oligos are self-deliverable and do not need any transfection reagents or delivery agents and can work both in in vitro and in vivo models. AUM’s FANA ASO technology also provides next-generation solutions for genetic research in agriculture and entomology. AUM BioTech is headquartered in Philadelphia, Pennsylvania, USA. Follow the company on Twitter @aumbiotech, LinkedIn, and Facebook.
